CNS specialty pharma selling epilepsy, ADHD and Parkinson's drugs including Qelbree and Trokendi XR.
CNS specialty pharma selling epilepsy, ADHD and Parkinson's drugs including Qelbree and Trokendi XR.
Sells branded prescription drugs in the US through its own sales force, with reported sales net of rebates paid to insurers and pharmacy middlemen. Its older epilepsy products are mature and exposed to generic copies, so growth rests on newer drugs. It bought Sage Therapeutics in 2025, adding a postpartum depression drug sold through a Biogen partnership.
Moat: narrow (IP / patents, distribution). Extended-release formulation patents and an established CNS sales force protect share.
Headquarters: Rockville, Maryland, US · Founded: 2005 · Employees: 838
Size Supernus Pharmaceuticals (SUPN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.02B, the 1054th largest of 3,085 United States companies the cockpit tracks. Shares closed at $28.96 on 18 Nov 2026.
Performance Over six months the shares fell 40.5%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 16.4% over the last twelve months (peer median +11.6%); the operating margin is 45.0% (peer median 17.2%).
Valuation It trades at 8.0× forward earnings against a peer median of 24.4× (2nd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -8 pp: the price already allows for a slowdown.
Short interest Short interest is 3.7% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.37B | $1.24B | $1.19B | $1.09B | $901M |
| Revenue growth | — | +4% | +9% | +21% | — |
| Gross profit | $1.17B | $1.02B | $977M | $919M | $729M |
| EBITDA | $633M | $378M | $298M | $249M | $230M |
| Net income | $450M | $210M | $7.00M | -$129M | -$53.0M |
| Free cash flow | $26.0M | -$93.0M | $7.00M | -$308M | -$9.00M |
| Capital expenditure | $64.4M | $67.0M | $31.0M | $53.0M | $6.00M |
| Total debt | $501M | $351M | $375M | $283M | $277M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals SUPN | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% |
| Amneal Pharmaceuticals AMRX | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% |
| Neurocrine Biosciences NBIX | $16.5B | +5% | +38% | 25% | 18.0× | -1.5% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SUPN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.8% | -0.3% | 2nd lowest of 21 |
| 6-month return | -40.5% | -0.4% | 2nd lowest of 20 |
| Distance from 52-week high | -51.5% | -21.1% | 3rd lowest of 21 |
| Revenue growth (TTM) | +16.4% | +11.6% | 7th highest of 17 |
| Operating margin | 45.0% | 17.2% | 3rd highest of 18 |
| Forward P/E | 8.0× | 24.4× | 2nd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 6.2% | 0.9% | 5th most demanding of 11 |
| Growth delivered (Del g) | +13.9% | +10.3% | 4th highest of 11 |
| Hurdle (Req g minus delivered) | -7.7 pp | -5.6 pp | 6th least demanding of 11 |
| EV / EBITDA | 9.8× | 23.3× | 2nd cheapest of 9 |
| Net debt / EBITDA | 0.3× | 0.9× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% | +57.9% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |